Akero Therapeutics Inc (AKRO)
19.94
-0.80
(-3.84%)
USD |
NASDAQ |
May 17, 16:00
19.94
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics SG&A Expense (TTM): 33.41M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 33.41M |
| December 31, 2023 | 31.07M |
| September 30, 2023 | 29.69M |
| June 30, 2023 | 32.71M |
| March 31, 2023 | 31.30M |
| December 31, 2022 | 29.87M |
| September 30, 2022 | 27.50M |
| June 30, 2022 | 21.38M |
| March 31, 2022 | 20.14M |
| December 31, 2021 | 19.13M |
| September 30, 2021 | 18.47M |
| Date | Value |
|---|---|
| June 30, 2021 | 17.75M |
| March 31, 2021 | 16.18M |
| December 31, 2020 | 15.24M |
| September 30, 2020 | 14.25M |
| June 30, 2020 | 12.51M |
| March 31, 2020 | 10.74M |
| December 31, 2019 | 8.605M |
| September 30, 2019 | 6.507M |
| June 30, 2019 | 4.557M |
| March 31, 2019 | 3.15M |
| December 31, 2018 | 1.896M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.557M
Minimum
Jun 2019
33.41M
Maximum
Mar 2024
20.05M
Average
18.80M
Median
SG&A Expense (TTM) Benchmarks
| 89bio Inc | 32.60M |
| Madrigal Pharmaceuticals Inc | 172.76M |
| Viking Therapeutics Inc | 37.46M |
| Ionis Pharmaceuticals Inc | 239.74M |
| Galectin Therapeutics Inc | 5.993M |